90Yttrium radioembolisation for hepatocellular carcinoma and colorectal liver metastases
Rizell M, Hultborn R, Bernhardt P, Svensson J, Sternby Eilard M, Samuelsson O, Strandell A, Svanberg T, Wikberg-Adania U
Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
Rizell M, Hultborn R, Bernhardt P, Svensson J, Sternby Eilard M, Samuelsson O, Strandell A, Svanberg T, Wikberg-Adania U. 90Yttrium radioembolisation for hepatocellular carcinoma and colorectal liver metastases. Gothenburg: The Regional Health Technology Assessment Centre (HTA-centrum). HTA-rapport 2010:27 . 2010
Authors' objectives
Does treatment with 90Yttrium microspheres prolong life in comparison with conventional salvage treatment, such as chemoembolisation or other palliative treatments, in patients with primary liver cancer or liver metastases from colorectal cancer?
Authors' conclusions
Brachytherapy using radioembolisation with 90Yttrium-labeled microspheres has been assessed in two categories of patients; in patients with unresectable primary hepatocellular carcinoma and in patients with liver metastases from colorectal cancer. The level of evidence of the effects on survival is very low for both these cancer forms. The level of evidence of a positive effect on tumour response in liver metastases from colorectal cancer is low, whereas the level of evidence of tumour response in hepatocellular carcinoma is very low. The increase in cost is moderate if the method is used instead of chemoembolisation in HCC patients. If it is used as an additive treatment in CRC patients the increase in cost is significant.
The Regional Health Technology Assessment Centre, Region Vastra Gotaland, HTA-centrum, Roda Straket 8, Sahlgrenska Universitetssjukhuset, 413 45 GOTHENBORG, Sweden Email: hta-centrum@vgregion.se
